Does warfarin or rivaroxaban at low anticoagulation intensity provide a survival benefit to Asian patients with atrial fibrillation?
D Lin, Y Chen, J Yong, S Wu, Y Zhou, W Li… - Frontiers in …, 2021 - frontiersin.org
Background: Low-dose rivaroxaban and low-intensity warfarin are widely used in Asia for
patients with atrial fibrillation (AF). However, in Asians, it is unclear whether low-dose …
patients with atrial fibrillation (AF). However, in Asians, it is unclear whether low-dose …
Effectiveness and safety of standard-and low-dose rivaroxaban in Asians with atrial fibrillation
YC Lin, SC Chien, YC Hsieh, CM Shih, FY Lin… - Journal of the American …, 2018 - jacc.org
Abstract Background: Low-dose rivaroxaban (10 mg/day) has been widely used in Asia for
patients with atrial fibrillation (AF), although there is a lack of evidence regarding its …
patients with atrial fibrillation (AF), although there is a lack of evidence regarding its …
A Comparative Study of the Clinical Benefits of Rivaroxaban and Warfarin in Patients With Non-valvular Atrial Fibrillation With High Bleeding Risk
PH Liu, ZH Liu, MH Niu, P Chen, YB Shi… - Frontiers in …, 2022 - frontiersin.org
Objective To compare the clinical benefits of rivaroxaban and warfarin in patients with non-
valvular atrial fibrillation (NVAF) with high bleeding risk. Methods A retrospective study was …
valvular atrial fibrillation (NVAF) with high bleeding risk. Methods A retrospective study was …
Benefits and harms of low-dose rivaroxaban in Asian patients with atrial fibrillation: a systematic review and meta-analysis of real-world studies
J Qian, YD Yan, SY Yang, C Zhang, WY Li… - Frontiers in …, 2021 - frontiersin.org
Background: Low-dose prescription of rivaroxaban was common among patients with atrial
fibrillation (AF) in Asia. However, the benefits and harms of rivaroxaban at a low dosage in …
fibrillation (AF) in Asia. However, the benefits and harms of rivaroxaban at a low dosage in …
Rivaroxaban vs. Warfarin in Japanese Patients With Non-Valvular Atrial Fibrillation in Relation to Age–Insight From J-ROCKET AF–
M Hori, M Matsumoto, N Tanahashi… - Circulation …, 2014 - jstage.jst.go.jp
Background: The J-ROCKET AF study found that rivaroxaban was non-inferior to warfarin
with respect to the principal safety outcome in patients with atrial fibrillation (AF). The aim of …
with respect to the principal safety outcome in patients with atrial fibrillation (AF). The aim of …
Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AF
AS Barnett, DD Cyr, SG Goodman, BS Levitan… - International journal of …, 2018 - Elsevier
Aims The aim of this study was to determine the net clinical benefit (NCB) of rivaroxaban
compared with warfarin in patients with atrial fibrillation. Methods This was a retrospective …
compared with warfarin in patients with atrial fibrillation. Methods This was a retrospective …
Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation
Background Rivaroxaban is an oral anticoagulant approved in the US for prevention of
stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF). We …
stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF). We …
Thromboembolic and major bleeding events with rivaroxaban versus warfarin use in a real-world setting
G Russo-Alvarez, KA Martinez… - Annals of …, 2018 - journals.sagepub.com
Background: Although randomized trials demonstrate the noninferiority of rivaroxaban
compared with warfarin in the context of nonvalvular atrial fibrillation (AF), little is known …
compared with warfarin in the context of nonvalvular atrial fibrillation (AF), little is known …
Reduced-Dose Rivaroxaban Is Associated with Lower All-Cause Mortality in Older Patients with Nonvalvular Atrial Fibrillation
Background: Reduced-dose rivaroxaban (10 mg) was used in the J-ROCKET AF trial,
demonstrating safety in the Asian population. It remains unclear whether treatment with …
demonstrating safety in the Asian population. It remains unclear whether treatment with …
Efficacy and safety of rivaroxaban versus warfarin in patients from mainland China with nonvalvular atrial fibrillation: a subgroup analysis from the ROCKET AF trial
Y Sun, D Hu, S Stevens, Y Lokhnygina, RC Becker… - Thrombosis research, 2017 - Elsevier
Abstract Background The ROCKET AF study evaluated once-daily rivaroxaban versus dose-
adjusted warfarin for the prevention of stroke and systemic embolism in patients with atrial …
adjusted warfarin for the prevention of stroke and systemic embolism in patients with atrial …